Inhalable levodopa given green light

Inhalable levodopa given green light
The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable levodopa powder created by US biotech company Acorda Therapeutics – for intermittent treatment. INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of carbidopa or levodopa, which are known as ‘off’ episodes. It is the first inhaled levodopa to be approved by the FDA ... read more
Source: Parkinson’s Life EUPublished on 2019-01-09By admin